Emerging experience with meningococcal serogroup B protein vaccines
Introduction: The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-05-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/14760584.2017.1308828 |
| _version_ | 1797680417471463424 |
|---|---|
| author | Daniela Toneatto Mariagrazia Pizza Vega Masignani Rino Rappuoli |
| author_facet | Daniela Toneatto Mariagrazia Pizza Vega Masignani Rino Rappuoli |
| author_sort | Daniela Toneatto |
| collection | DOAJ |
| description | Introduction: The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials. Continuing uncertainties exist around the appropriate age groups to be immunized, the degree and duration of efficacy, and the impact on nasopharyngeal carriage which has implications for strategies to interrupt transmission and maximize herd protection effects. Universal vaccination programs such as those undertaken in Quebec and the United Kingdom are providing important information on these issues. The potential for MenB vaccines to prevent infection by other serogroups appears promising, and the impact of MenB vaccines on other pathogenic neisserial species with similar surface proteins warrants further investigation. |
| first_indexed | 2024-03-11T23:29:43Z |
| format | Article |
| id | doaj.art-6927c0ce06c44b0caf220fdab2dfa479 |
| institution | Directory Open Access Journal |
| issn | 1476-0584 1744-8395 |
| language | English |
| last_indexed | 2024-03-11T23:29:43Z |
| publishDate | 2017-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj.art-6927c0ce06c44b0caf220fdab2dfa4792023-09-20T10:18:02ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952017-05-0116543345110.1080/14760584.2017.13088281308828Emerging experience with meningococcal serogroup B protein vaccinesDaniela Toneatto0Mariagrazia Pizza1Vega Masignani2Rino Rappuoli3Clinical RDC Italy Department, GSKPreclinical R&D IT Department, GSKVxR&D Discovery Performance Unit, GSKResearch & Development, GSKIntroduction: The successful development of two broadly protective vaccines targeting Neisseria meningitidis serogroup B (MenB); 4CMenB and rLP2086, is the most significant recent advance in meningococcal disease prevention. Areas covered: Here we review the principles underlying the development of each vaccine and the novel methods used to estimate vaccine coverage. We update clinical and post-licensure experience with 4CMenB and rLP2086. Expert commentary: The immunogenicity and acceptable safety profile of 4CMenB and rLP2086 has been demonstrated in clinical trials. Continuing uncertainties exist around the appropriate age groups to be immunized, the degree and duration of efficacy, and the impact on nasopharyngeal carriage which has implications for strategies to interrupt transmission and maximize herd protection effects. Universal vaccination programs such as those undertaken in Quebec and the United Kingdom are providing important information on these issues. The potential for MenB vaccines to prevent infection by other serogroups appears promising, and the impact of MenB vaccines on other pathogenic neisserial species with similar surface proteins warrants further investigation.http://dx.doi.org/10.1080/14760584.2017.13088284cmenbcarriageimmunogenicitymatsmeasuremeningococcal serogroup bneisseria meningitidisreverse vaccinologyrlp2086strain coverage |
| spellingShingle | Daniela Toneatto Mariagrazia Pizza Vega Masignani Rino Rappuoli Emerging experience with meningococcal serogroup B protein vaccines Expert Review of Vaccines 4cmenb carriage immunogenicity mats measure meningococcal serogroup b neisseria meningitidis reverse vaccinology rlp2086 strain coverage |
| title | Emerging experience with meningococcal serogroup B protein vaccines |
| title_full | Emerging experience with meningococcal serogroup B protein vaccines |
| title_fullStr | Emerging experience with meningococcal serogroup B protein vaccines |
| title_full_unstemmed | Emerging experience with meningococcal serogroup B protein vaccines |
| title_short | Emerging experience with meningococcal serogroup B protein vaccines |
| title_sort | emerging experience with meningococcal serogroup b protein vaccines |
| topic | 4cmenb carriage immunogenicity mats measure meningococcal serogroup b neisseria meningitidis reverse vaccinology rlp2086 strain coverage |
| url | http://dx.doi.org/10.1080/14760584.2017.1308828 |
| work_keys_str_mv | AT danielatoneatto emergingexperiencewithmeningococcalserogroupbproteinvaccines AT mariagraziapizza emergingexperiencewithmeningococcalserogroupbproteinvaccines AT vegamasignani emergingexperiencewithmeningococcalserogroupbproteinvaccines AT rinorappuoli emergingexperiencewithmeningococcalserogroupbproteinvaccines |